FogPharma

We were very proud to have #TeamFogPharma along with our families and friends walking in the Boston Pride Parade on Saturday! The event was a joyful experience in celebrating #PrideMonth, honoring the rich history and many local activists past and present who champion the rights of LGBTQ+ people worldwide, and demonstrating Fog’s commitment to advancing equity and inclusivity for the LGBTQ+ community.

Don’t miss FogPharma at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mathai Mammen, M.D., Ph.D. will give a company presentation on Monday, June 10, sharing the latest on Fog’s ongoing clinical trial of FOG-001, our preclinical pipeline of novel cancer therapeutics, and the exceptional potential of our Helicon peptide technology. Hope to see you there! 

FogPharma CEO Mathai Mammen, M.D., Ph.D. was honored by Timmerman Report among an inspiring group of fellow Asian American & Pacific Islander biopharma leaders to celebrate #AAPIHeritageMonth.    A diverse biopharma industry is essential if we are to create extraordinary medicines. Enriching our industry’s leadership with perspectives from AAPI and other historically underrepresented groups will enrich our cross-cultural fluency and ultimately our ability to achieve our mission to make a transformative impact for people and patients from all backgrounds.   https://bit.ly/3Kn3N70     #AAPIrepresentation #diversity #inclusion

Last week, Fog gathered for our first two-day company retreat in Meredith, NH, on Lake Winnipesaukee. The theme of the offsite was “Connect, Inspire, Innovate” where we kicked off the time with a conversation with a patient-care partner couple, Tracy and Jason Binder. Their story and experiences of living with cancer reminded us of our purpose and the urgent need for new, more effective treatments. We also spent time learning from each other about the innovative projects and solutions happening across the organization and coming up with ways to further our mission over the next several years.    Most importantly, the offsite allowed us to deepen the connections between us that power our work each day and enable us to create extraordinarily impactful medicines.      Check out some of the highlights from our time together! 👇☀️🌳 #TeamFogPharma #teamdevelopment 

Please join us as Kyri Papadopoulos, M.D., from The START Center for Cancer Care presents our Trials in Progress poster at #ASCO2024 this weekend in Chicago, IL! Dr. Papadopoulos will be presenting the design of our first-in-human (FIH) Phase 1/2 trial of FOG-001, a first-in-class inhibitor of β-catenin that directly blocks β-catenin’s interaction with the T-cell factor (TCF) family of transcription factors, the most downstream node in the Wnt pathway.   The ASCO annual conference gathers leaders from around the world to share the latest advancements in oncology and provides an opportunity to forge connections with others who are as passionate about transforming what is possible for cancer patients as we are. Our abstract and presentation location can be found at: https://bit.ly/4bTAQMt   #drugdiscovery #oncology #cancerresearch

Congratulations to the talented chemists on #TeamFogPharma who will be heading to grad school: Lia Baker to Columbia, Jesper Andersson to UCLA, and Gregory Valtierra to MIT! They've each been vital contributors to building our team and driving forward our Helicon research, and we’re sure they’ll make the same big impact in their graduate studies and beyond.   At Fog, we’re big believers in growth mindset and lifelong learning. We’re so proud that these scientists will be continuing their education and taking their learnings from Fog forward into their future careers. #drugdiscovery #oncology #biotechnology

We’re thrilled to announce a collaboration with the world-class team at ARTBIO that expands our pipeline of cancer therapies into #radiopharmaceuticals, a class of drugs we believe will make an extraordinary impact on patient outcomes. Along with ARTBIO we will be co-creating and co-commercializing Helicon-enabled alpha-particle radioligand therapies, drawing on the unique strengths of each of our platforms to produce a new category of targeted radioligand therapy. We believe the combination could produce the best radiopharmaceutical platform that exists in our industry today: On the one side, ARTBIO is uniquely able to accomplish distributed manufacturing of lead-212 (²¹²Pb), one of the most promising isotopes for radiopharmaceutical use but that is challenging to utilize because of its short half-life. On the other side, Fog’s Helicon platform could be a best-in-class carrier of radiopharmaceuticals because of our ability to precisely tune our peptides to control tissue distribution and half-life. The general hyper-tunability of Helicons opens new possibilities both for intracellular targeting — where Fog’s wholly-owned pipeline is focused — as well as for extracellular delivery. At the intersection of these two unmatched platforms, there’s huge potential to create therapies that improve, extend and save the lives of people with cancer. Learn more in our press release: https://bwnews.pr/3wBXF7L #radioligandtherapy #cancer #oncology #peptides #Helicons #radiopharmaceutical #patients

This week at #TIDESUSA, Yaguang Si, Ph.D., FogPharma’s Senior Director, Biology, will present on our preclinical development of Helicons™ as a potential treatment for cancer.    FOG-001, which is now in a first-in-human Phase 1/2 study, represents a long sought-after therapeutic approach in #cancer because of its ability to directly inhibit the β-catenin:TCF interaction that drives many cancers. YaGuang will present on our preclinical development of Helicon β-catenin inhibitors as novel alternatives for a range of cancers resulting from aberrant transcriptional signaling via β-catenin. https://bit.ly/3UAMXaM     #drugdiscovery #oncology #biotechnology

We’re #hiring for 4 exciting roles in our technical operations team, supporting the development, manufacturing, and supply of Fog’s investigational medicines in current and future research and clinical studies. We’re looking for company-builders who can leverage Fog’s unique position and opportunity to deliver life-changing medicines for patients with devastating diseases. We’re specifically hiring the following positions:   - Vice President, Manufacturing, a highly influential role reporting to Chief Technical Operations Officer Rohin Mhatre, Ph.D., who will make a significant impact managing our manufacturing network and directing our manufacturing strategy to enable cost-effective supply of clinical and future commercial products worldwide.    - Director, Clinical Supply Operations, who will ensure high-quality and consistent supply of our investigational medicines as we prosecute clinical trials for first-in-class cancer therapies.   - Principal Associate Scientist (Formulation), who will conduct studies to develop and implement fit-for-purpose formulations for our investigational Helicon therapeutics. - Process Chemist, who will establish robust manufacturing processes for Fog’s therapeutic candidates by leveraging modern synthetic methodology.    Learn more about these roles: https://bit.ly/3VSwmAx         #biotechjobs #drugdiscovery #technicaloperations

FogPharma CEO Mathai Mammen, M.D., Ph.D., will be at the rEVOLUTION Symposium this week in Washington, DC, to moderate a panel on the inevitability and utility of AI in the development of therapies for patients. The rEVOLUTION meeting is held every 1-2 years in DC, and brings together thought leaders to tackle some of R&D’s most significant challenges. The location also allows significant participation by DC’s policymakers and regulators.   Joining Mathai for this important discussion will be Nicolle Gatto, Ph.D., Chief Scientific Officer at Aetion; Najat Khan, PhD, Former Chief Data Science Officer & Global Head, Strategy & Portfolio, R&D at Johnson & Johnson; Eric Schadt, Ph.D., Chief Scientific Officer at Pathos; and other leaders.    AI, and data science broadly, are technologies we’re passionate about at FogPharma. Today, a lot of attention is being paid to the role of data science in drug discovery, but in fact some of the biggest gains in the near term will be made in drug development. Numerous resource-intensive, strategically critical drug development challenges — including clinical site selection, patient recruitment, protocol design, endpoint definition, responder and non-responder signatures, and synthetic control arms — will be revolutionized by data science in the coming years.   At Fog, we hope to combine experimental science and these sorts of data science advances to revolutionize the discovery and development of transformational medicines.    Explore the rEVOLUTION event agenda here:  https://bit.ly/44jUIoH   #drugdiscovery #artificialIntelligence #datascience #oncology